Kiniksa Pharmaceuticals (KNSA) Insider Trading & Ownership $26.89 +0.94 (+3.62%) Closing price 04:00 PM EasternExtended Trading$26.90 +0.00 (+0.02%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Kiniksa Pharmaceuticals (NASDAQ:KNSA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage54.57%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$14.35 M Get KNSA Insider Trade Alerts Want to know when executives and insiders are buying or selling Kiniksa Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KNSA Insider Buying and Selling by Quarter Kiniksa Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/19/2025Eben TessariCOOSell12,000$26.41$316,920.00 5/13/2025Sanj K PatelCEOSell2,872$27.03$77,630.16 5/8/2025Sanj K PatelCEOSell101$27.00$2,727.00 5/7/2025John F PaoliniInsiderSell200$27.00$5,400.00 5/7/2025Michael R MegnaCAOSell17,647$26.69$470,998.43 5/5/2025Ross MoatInsiderSell6,272$28.00$175,616.00 5/1/2025Ross MoatInsiderSell23,234$28.02$651,016.68 4/30/2025Mark RagosaCFOSell21,254$26.95$572,795.30 4/29/2025Ross MoatInsiderSell64,035$25.21$1,614,322.35 4/21/2025Ross MoatInsiderSell18,259$20.29$370,475.11 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 4/14/2025Eben TessariCOOSell12,000$20.48$245,760.00 3/19/2025Mark RagosaCFOSell8,879$23.10$205,104.90 3/17/2025Mark RagosaCFOSell11,464$23.10$264,818.40 3/12/2025Mark RagosaCFOSell36,372$22.25$809,277.00 3/12/2025Michael R MegnaCAOSell9,051$22.45$203,194.95 2/10/2025Eben TessariCOOSell14,000$19.57$273,980.00 1/13/2025Eben TessariCOOSell14,000$18.24$255,360.00 12/5/2024Mark RagosaCFOSell1,123$21.25$23,863.75 12/3/2024Mark RagosaCFOSell8,969$21.45$192,385.05 10/15/2024Eben TessariCOOSell17,000$26.87$456,790.00 9/23/2024Eben TessariCOOSell17,500$24.99$437,325.00 9/3/2024John F PaoliniInsiderSell60,692$26.12$1,585,275.04 8/27/2024Eben TessariCOOSell17,500$26.91$470,925.00 7/23/2024John F PaoliniInsiderSell22,000$26.32$579,040.00 7/23/2024Mark RagosaCFOSell24,248$24.79$601,107.92 7/23/2024Sanj K PatelCEOSell136,124$25.65$3,491,580.60 (Data available from 1/1/2013 forward) KNSA Insider Trading Activity - Frequently Asked Questions Who is on Kiniksa Pharmaceuticals's Insider Roster? The list of insiders at Kiniksa Pharmaceuticals includes Barry D. Quart, Eben Tessari, John F Paolini, Mark Ragosa, Michael R Megna, Ross Moat, and Sanj K Patel. Learn more on insiders at KNSA. What percentage of Kiniksa Pharmaceuticals stock is owned by insiders? 54.57% of Kiniksa Pharmaceuticals stock is owned by insiders. Learn more on KNSA's insider holdings. Which Kiniksa Pharmaceuticals insiders have been selling company stock? The following insiders have sold KNSA shares in the last 24 months: Eben Tessari ($2,457,060.00), John F Paolini ($3,236,577.04), Mark Ragosa ($2,909,352.32), Michael R Megna ($1,490,853.45), Ross Moat ($2,811,430.14), and Sanj K Patel ($3,962,985.34). How much insider selling is happening at Kiniksa Pharmaceuticals? Insiders have sold a total of 705,891 Kiniksa Pharmaceuticals shares in the last 24 months for a total of $16,868,258.29 sold. Kiniksa Pharmaceuticals Key ExecutivesMr. Sanj K. Patel (Age 55)CEO & Chairman of the Board Compensation: $1.57M2 recent tradesMr. Eben Tessari (Age 42)Senior VP & COO Compensation: $733.29k4 recent tradesDr. John F. Paolini FACC (Age 59)M.D., Ph.D., Senior VP & Chief Medical Officer Compensation: $855.79kMr. Mark Ragosa C.F.A. (Age 50)Senior VP & CFO Mr. Michael R. Megna CPA (Age 53)Chief Accounting Officer & Group VP of Finance 2 recent tradesMr. Chad MorinSenior VP & Chief Compliance OfficerMs. Madelyn Demsky Zeylikman (Age 50)SVP, General Counsel & Secretary More Insider Trading Tools from MarketBeat Related Companies BBIO Insider Transactions BPMC Insider Transactions ELAN Insider Transactions TGTX Insider Transactions VRNA Insider Transactions LNTH Insider Transactions AXSM Insider Transactions GRFS Insider Transactions NUVL Insider Transactions ADMA Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Turbulence for Joby Shares: What's Behind the Recent Dip?UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?Sprouts Stock: Insider Sales, But Strong Bullish Signals5 Hot Small-Cap Insiders Bought at the Peak of Tariff FearsThe Top-Ranked Insider Buys From April by Market Cap This page (NASDAQ:KNSA) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
